(Q45981877)

18 December 2017

title

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. (English)

1 reference

18 December 2017

1 reference

Lauren C Harshman

1

1 reference

18 December 2017

Sandy Srinivas

series ordinal

2

1 reference

18 December 2017

Aya Kamaya

series ordinal

3

1 reference

18 December 2017

Benjamin I Chung

series ordinal

4

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

18 December 2017

published in

Nature Reviews Urology

1 reference

18 December 2017

volume

6

1 reference

18 December 2017

issue

6

1 reference

18 December 2017

page(s)

338-343

1 reference

18 December 2017

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

31 March 2020

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Results of Inferior Vena Cava Resection for Renal Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Long-term results of resection of renal cell cancer with extension into inferior vena cava

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Surgical treatment of renal cancer with vena cava extension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Sunitinib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.84

Cytotoxic chemotherapy for advanced renal cell carcinoma.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19498412

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19498412

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRUROL.2009.84

1 reference

18 December 2017

Dimensions Publication ID

1001066389

0 references

1 reference

18 December 2017